Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
Healthy Returns: Wall Street mulls over Amgen’s weight loss drug data
CNBC December 5, 2024
Wall Street is chewing over critical data released last week on Amgen’s experimental weight loss injection – a potential competitor in the blockbuster obesity drug market.
Some analysts said the initial mid-stage trial results appear positive overall. But questions remain about the drug’s efficacy and how well patients tolerate it, they noted.
We likely won’t get more answers until the company releases the full data from the study. That includes results from a second part of the trial, which examines how long MariTide’s weight loss lasts.
Investors initially weren’t pleased. Shares of Amgen tumbled more than 11% as the markets opened last Tuesday, as the results appeared to be slightly below Wall Street’s lofty expectations for the...
Today's Sponsors
Today's Sponsor